Introduction {#s2}
============

Approximately 40%--60% of HIV-positive persons in developed countries continue to be diagnosed with HIV at a late stage of infection [@pmed.1001510-Girardi1]. According to the latest consensus definition from the HIV in Europe study group, late presenters are defined as persons presenting to a clinic that can prescribe antiretroviral therapy (ART) with a CD4 count of less than 350/mm^3^ or an AIDS defining illness [@pmed.1001510-Antinori1], the current World Health Organization\'s recommended threshold for initiation of ART [@pmed.1001510-World1]. Late presentation, which may reflect late diagnosis and/or late entry into care, has consequences both for the individual, in terms of poorer outcomes [@pmed.1001510-Battegay1]--[@pmed.1001510-Lanoy1], and for society in terms of the risk of onward transmission due to uncontrolled viremia and lack of awareness of HIV serostatus [@pmed.1001510-Quinn1],[@pmed.1001510-European1]. Late presentation also has an economic impact, with higher resource use, particularly in the first few months following presentation [@pmed.1001510-Krentz1],[@pmed.1001510-Fleishman1]. Barriers to testing from the patients perspective include concerns about the impact of a positive result, fears around discrimination, confidentiality, criminalisation of risk behaviours, and limited knowledge about accessing testing or treatment on testing positive [@pmed.1001510-Deblonde1]. Reported concerns by clinicians include language barriers, the belief that lengthy counselling is required, worry about informing individuals of a HIV-positive test result, and lack of knowledge about HIV and potential risk behaviours [@pmed.1001510-Yazdanpanah1].

Many studies have presented data on late presentation, generally focusing on a specific country or region within a country and applying various definitions for late presentation. Data from Eastern Europe is particularly scarce and hence a Europe-wide perspective of late presentation using uniform definitions can help inform policy and decision making on future continent-wide HIV testing strategies. Such results will provide a platform for future monitoring of late presentation following appropriate interventions.

The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study provides a unique opportunity to describe the epidemiology of those testing HIV positive at a late stage of HIV infection compared to those testing earlier, and to look at regional differences within HIV exposure groups. The aims of the present analyses were to describe trends in late presentation over time in different regions of Europe and according to HIV exposure group, and to investigate the clinical consequences of late presentation.

Methods {#s3}
=======

Patients {#s3a}
--------

COHERE is a collaboration of 33 cohorts from across Europe and is part of the EuroCoord network ([www.EuroCoord.net](http://www.EuroCoord.net)). COHERE was established in 2005 with the aim of conducting epidemiological research on the prognosis and outcome of HIV-positive persons, which the individual contributing cohorts cannot address themselves because of sample size or heterogeneity of specific subgroups of HIV-positive persons. Local ethical committee and/or other regulatory approval were obtained as applicable according to local and/or national regulations in all participating cohorts unless no such requirement applied to observational studies according to national regulations. Each cohort submits data using the standardized HIV Collaboration Data Exchange Protocol (HICDEP) [@pmed.1001510-Kjaer1], including information on patient demographics, use of cART, CD4 counts, AIDS, and deaths. Further details can be found at <http://www.eurocoord.net/partners/founding_networks/cohere.aspx>.

Twenty three cohorts across 35 European countries provided data for the present analysis. All persons aged ≥16 y, who presented for care (earliest of HIV diagnosis, first clinic visit, or enrolment into the participating cohort) for the first time after 1 January 2000 until 1 January 2011 were included. Baseline was defined as the date of first HIV diagnosis, or the earliest of first clinic visit or cohort enrolment if date of HIV diagnosis was missing, referred to as date of HIV diagnosis. Persons were excluded if gender or HIV diagnosis was missing, if aged \<16 y, or where there was evidence of an earlier HIV diagnosis (CD4 count, AIDS diagnosis, or starting ART) more than 1 mo prior to first clinic visit, as were persons from Argentinean centres in EuroSIDA and persons from the seroconverter cohorts in COHERE, because by definition, such persons are not presenting late.

Late presentation was defined as a person diagnosed with HIV with a CD4 count below 350/mm^3^ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late presentation with advanced disease was defined as a person diagnosed with HIV with a CD4 count below 200/mm^3^or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis [@pmed.1001510-Antinori1]. Delayed entry into care was defined as ≥3 mo between HIV diagnosis and first clinic visit, in those where both dates were recorded. All persons were required to have at least one CD4 count measured in the 6 mo following diagnosis.

Statistical Methods {#s3b}
-------------------

Baseline characteristics of late presenters were compared to non-late presenters and logistic regression was used to identify factors associated with late presentation and late presentation with advanced disease. Factors investigated were age, HIV-exposure group (males having sex with males \[MSM\], heterosexual male, heterosexual female, male intravenous drug user \[IDU\], female IDU, other \[including patients with unknown HIV exposure group, likely to include a number of IDUs, MSMs, and heterosexuals\]), region of origin (Europe, Africa, other \[including patients from Central/Southern America and Asia\], unknown), European region of HIV diagnosis (based on the cohort location and defined as: South: Greece, Israel, Italy, Portugal, and Spain; Central: Austria, Belgium, France, Germany, Luxemburg, and Switzerland; North: Denmark, Finland, Ireland, Netherlands, Norway, Sweden, and UK; East: Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine), calendar year of diagnosis, and delayed entry into care. *A priori*, we were interested in comparing changes over time within European regions and HIV exposure groups, and performed formal tests of interaction before presenting the stratified analyses. Logistic regression was also used to identify characteristics associated with delayed entry into care among late presenters.

Kaplan Meier survival analysis was used to estimate the probability of the composite endpoint of a new AIDS defining event/deaths and Poisson regression models to evaluate the incidence of AIDS/death. Models were adjusted for the same factors as above, and additionally the effect of time after HIV diagnosis (\<1, 1--2, \>2 y). Recurrent AIDS events were not collected by all participating cohorts and thus were not included.

Different sensitivity analyses were performed to assess the robustness of our findings. Analyses were repeated excluding persons where date of HIV infection was not available in the dataset and excluding persons with known delayed entry into care. We also assessed how the proportion of late presenters changed by using a different time window around the CD4 count at HIV diagnosis (1 mo, 12 mo) and also assuming those without a CD4 count measured were late presenters or not.

All analyses were performed using Statistical Analysis Software Version 9.3 (Statistical Analysis Software).

Results {#s4}
=======

Of 107,735 persons in COHERE diagnosed with HIV after 1 January 2000, 84,524 were included in these analyses (78.5%; [Table S1](#pmed.1001510.s001){ref-type="supplementary-material"}). Persons were primarily excluded because they lacked information on CD4 count at HIV diagnosis. Excluded persons were more likely to be from "other" HIV exposure groups (i.e., not categorised as MSM, IDU, or heterosexual), from Eastern Europe, younger, to have no prior AIDS diagnosis at diagnosis, diagnosed in earlier calendar years, and less likely to die. Characteristics of the 84,524 included persons are shown in [Table 1](#pmed-1001510-t001){ref-type="table"}; 45,488 persons were classified as late presenters (53.8%) and 28,081 (33.2%) as late presenters with advanced disease. The highest proportion of late presenters was among heterosexual males (66.1%; 11,158/16,875), persons from clinics in Southern Europe (57.0%; 4,447/7,796), and persons originating from Africa (65.1%; 7,708/11,833). 11,903 of the late presenters had AIDS at HIV-1 diagnosis (20.6%), the most common diagnoses were *Pneumocystis jiroveci* pneumonia (20.6%; 2,457/11,903), cytomegalovirus (excluding retinitis, 13.9%; 1,657/11,903), and oesophageal candidiasis (12.3%; 1,463/11,903). Among the 34,561 persons with data on both date of HIV diagnosis and first contact with a clinic, 7.9% (2,720/34,561) had delayed entry into care. Among late presenters, 7.4% had delayed entry into care (1,408/18,933); such individuals were younger (adjusted odds ratio (aOR 0.87/10 y older; 95% CI 0.83--0.91), presented later (aOR 0.96/year later; 95% CI 0.94--0.97), and were more likely to be under care in Southern Europe compared to Northern Europe (aOR 2.02; 95% CI 1.77--2.30). HIV exposure group or region of origin were not associated with delayed entry into care among late presenters.

10.1371/journal.pmed.1001510.t001

###### Characteristics at HIV diagnosis of late presenters and late presenters with advanced disease: COHERE 2000--2011.

![](pmed.1001510.t001){#pmed-1001510-t001-1}

  Characteristics                                            Subcharacteristics     All     Late Presenters   Late Presents with Advanced Disease                        
  --------------------------------------------------------- --------------------- -------- ----------------- ------------------------------------- ------------ -------- ------------
  All                                                                              84,524         100                       45,488                     53.8      28,081      33.2
  HIV exposure group                                                MSMs           32,761        38.8                       14,317                     43.7      7,924       24.2
                                                              Male heterosexual    16,875        20.0                       11,158                     66.1      7,723       45.8
                                                             Female heterosexual   20,131        23.8                       11,479                     57.0      6,788       33.7
                                                                  Male IDU         4,142          4.9                        2,393                     57.8      1,651       39.9
                                                                 Female IDU        1,413          1.7                         718                      50.8       453        32.1
                                                                 Male other        6,312          7.5                        3,678                     58.3      2,435       38.6
                                                                Female other       2,890          3.4                        1,745                     60.4      1,107       38.3
  European region of care                                           South          7,796          9.2                        4,447                     57.0      2,873       36.9
                                                                   Central         39,949        47.3                       21,729                     54.4      13,192      33.0
                                                                    North          35,583        42.1                       18,748                     52.7      11,673      32.8
                                                                    East           1,196          1.4                         564                      47.2       343        28.7
  Region of origin                                                 Europe          31,370        37.1                       16,163                     51.5      10,394      33.1
                                                                   Africa          11,833        14.0                        7,708                     65.1      4,770       40.3
                                                                    Other          5,812          6.9                        3,348                     57.6      2,157       37.1
                                                                   Unknown         35,509        42.0                       18,269                     51.5      10,760      30.3
  Delayed entry into care[a](#nt102){ref-type="table-fn"}                          2,720          7.9                        1,408                     7.4        767        6.6
                                                                                   Median         IQR                       Median                     IQR       Median      IQR
  Age                                                               Years            36         30--43                        38                      31--45       39       32--46
  CD4 count                                                        /mm^3^           333        160--523                       175                    70--270       94      36--160
  Baseline                                                       Month/year         5/05     10/02--11/07                    2/05                   8/02--8/07   11/04    6/02--6/07

Late presentation: diagnosed with HIV with a CD4 count below 350/mm^3^ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm^3^or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis.

Delayed entry into care: ≥3 mo between HIV diagnosis and first clinic visit, in those patients where both dates were recorded (*n* = 34,561). Baseline was defined as the earliest of HIV test, first study visit, or cohort enrolment. "Other" regions included Central/Southern America (*n* = 4,277) and Asia (*n* = 1,005). "Other" HIV male and female transmission groups included 5,350 (84.8%) and 2,046 (70.8%) patients with unknown HIV-exposure group, respectively, likely to include a number of IDUs, MSMs, and heterosexuals.

IQR, interquartile range.

Late presentation declined from 57.3% (4,222/7,367) in 2000 to 51.7% (1,665/3,223) in 2010/2011 ([Figure 1](#pmed-1001510-g001){ref-type="fig"}). The median CD4 count at diagnosis among all persons increased from 306/mm^3^ in 2000 to 363/mm^3^ in 2009. Factors associated with late presentation included older age (aOR 1.41/10 y older; 95% CI 1.39--1.43), and region of origin, with persons from Africa (aOR 1.75; 95% CI 1.66--1.84) and persons from other regions (aOR 1.40; 95% CI 1.32--1.48) having higher odds of late presentation compared to persons originating from Europe. Compared to persons from Central Europe, persons under care in Southern Europe (aOR 1.41; 95% CI 1.33--1.48) had higher odds of late presentation, as did all HIV-exposure groups compared to MSM. This ranged from over a doubling in heterosexual men (aOR 2.05; 95% CI 1.97--2.14) to 31% for female IDUs (aOR 1.31; 95% CI 1.18--1.46). Delayed entry into care was associated with decreased odds of late presentation (aOR 0.91; 95% CI 0.84--0.99). After adjustment for these confounders, there was a 4% decrease in the odds of late presentation per later calendar year (aOR 0.96; 95% CI 0.96--0.97). Results were similar for late presentation with advanced disease ([Figure 1](#pmed-1001510-g001){ref-type="fig"}), with a decrease in advanced disease at presentation of 5% per year after adjustment (aOR 0.95; 95% CI 0.94--0.95). Results were highly consistent excluding patients with unknown or delayed entry into care ([Table S2](#pmed.1001510.s002){ref-type="supplementary-material"}).

![Changes over time in late presentation and CD4 count at HIV diagnosis: COHERE 2000--2011.\
Late presentation: diagnosed with HIV with a CD4 count below 350/mm^3^ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm^3^or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis.](pmed.1001510.g001){#pmed-1001510-g001}

[Figure 2](#pmed-1001510-g002){ref-type="fig"} shows the crude percentage of late presenters within HIV-exposure groups, region, and calendar period, and the aOR of late presentation per year of later HIV diagnosis (also shown in [Table S3](#pmed.1001510.s003){ref-type="supplementary-material"}). Later calendar year was associated with a decrease in late presentation among MSM, and male and female heterosexuals in both Central and Northern Europe ([Figure 2B and 2C](#pmed-1001510-g002){ref-type="fig"}). For example, the proportion of MSMs with late presentation in Central Europe declined from 51.9% (1,201/2,312) in 2000/2001 to 40.4% (1,352/3,348)≥2008 (aOR 0.93 per year later; 95% CI 0.92--0.94) and from 48.1% (919/1,911) to 38.6% (1,731/4,484) in Northern Europe ([Figure 2C](#pmed-1001510-g002){ref-type="fig"}; aOR 0.95 per year later; 95% CI 0.94--0.96). Late presentation also decreased over time in heterosexual females from Eastern Europe from 55.6% (25/45) in 2000/2001 to 33.9% (20/59)≥2008 (aOR 0.89 per year later; 95% CI 0.80--0.98). Late presentation increased in male IDUs from Southern Europe ([Figure 2A](#pmed-1001510-g002){ref-type="fig"}; aOR 1.06 per year later; 95% CI 0.99--1.13), and also among male and female IDUs from Eastern Europe, although the aORs failed to reach statistical significance, possibly owing to the smaller number of patients from Eastern Europe.

![(A--D) Changes in late presentation over calendar time; stratified by HIV exposure group: COHERE 2000--2011.\
(A) Southern Europe. (B) Central Europe. (C) Northern Europe. (D) Eastern Europe. All models adjusted for age, delayed entry into care (≥3 mo) after HIV diagnosis, region of origin, European region of care, and HIV mode of infection. F, female; Het, heterosexual; M, male.](pmed.1001510.g002){#pmed-1001510-g002}

Results for presentation with advanced disease are summarised in [Table 2](#pmed-1001510-t002){ref-type="table"}. Within Southern Europe, late presentation with advanced disease decreased in MSMs from 36.5% (107/293) during 2000/2001 to 29.7% (364/1,226)≥2008 (aOR 0.94 per year later; 95% CI 0.92--0.97), but was stable in other infection groups. In Central Europe late presentation with advanced disease was decreasing in all HIV-exposure groups except male IDUs, and most rapidly in MSMs, from 33.0% (763/2,312) to 20.7% (693/3,348; aOR 0.91 per year later; 95% CI 0.90--0.92). Similar results were seen in Northern Europe, with a decrease over time in all HIV-exposure groups except male and female IDUs. There were no significant changes over time in Eastern Europe in the odds of late presentation with advanced disease.

10.1371/journal.pmed.1001510.t002

###### Percentage of late presenters with advanced disease and adjusted odds of late presentation with advanced disease associated with later calendar years of HIV diagnosis: a comparison across regions and HIV exposure group.

![](pmed.1001510.t002){#pmed-1001510-t002-2}

  Region of Care    HIV Exposure Group   2000--2001   2002--2003   2004--2005   2006--2007   ≥2008   Per Year Later HIV Diagnosis                                                                                   
  ---------------- -------------------- ------------ ------------ ------------ ------------ ------- ------------------------------ ------- ------ ------- ------ ------------------- ---------- ------------------- ----------
  South                    MSM              293          36.5         369          37.4       635                28.7                919    25.8   1,226   22.9   0.92 (0.89--0.94)   \<0.0001   0.94 (0.92--0.97)   \<0.0001
                          M Het             198          51.0         203          54.7       281                47.7                384    48.4    361    49.6   0.98 (0.95--1.02)     0.41     1.00 (0.96--1.04)     0.82
                          F Het             222          38.3         188          36.2       325                35.9                313    34.8    352    41.2   1.02 (0.98--1.06)     0.28     1.03 (0.99--1.07)     0.15
                          M IDU             218          42.2         122          48.4       160                48.8                143    46.2    106    50.0   1.03 (0.98--1.09)     0.20     1.00 (0.94--1.07)     0.92
                          F IDU              52          40.4          23          13.0       33                 30.3                27     33.3    21     38.1   1.01 (0.90--1.13)     0.88     0.95 (0.80--1.13)     0.55
                          Other             112          55.4         124          46.8       125                37.6                115    53.9    146    45.9   0.99 (0.94--1.04)     0.73     1.01 (0.95--1.07)     0.83
  Central                  MSM             2,312         33.0        2,460         27.8      2,912               25.1               3,070   20.1   3,348   20.7   0.92 (0.91--0.93)   \<0.0001   0.91 (0.90--0.92)   \<0.0001
                          M Het            1,949         44.8        2,078         46.4      1,910               43.3               1,570   42.4   1,425   41.7   0.98 (0.96--0.99)    0.0041    0.97 (0.96--0.98)   \<0.0001
                          F Het            2,359         31.8        2,705         33.0      2,407               32.0               1,915   28.9   1,499   29.6   0.98 (0.97--1.00)    0.024     0.97 (0.95--0.98)   \<0.0001
                          M IDU             469          36.5         351          36.5       339                44.5                236    37.7    207    39.1   1.01 (0.98--1.05)     0.43     0.99 (0.96--1.03)     0.80
                          F IDU             184          35.3         146          30.8       120                42.5                113    32.7    118    28.0   0.98 (0.93--1.04)     0.50     0.94 (0.89--0.99)    0.031
                          Other             832          44.8         819          40.9       828                41.3                662    36.6    606    37.5   0.96 (0.94--0.98)    0.0003    0.95 (0.93--0.98)   \<0.0001
  North                    MSM             1,911         29.3        2,244         25.2      3,042               24.6               3,289   20.6   4,484   19.1   0.94 (0.93--0.95)   \<0.0001   0.92 (0.90--0.93)   \<0.0001
                          M Het            1,064         49.3        1,186         51.0      1,269               51.8               1,184   46.2   1,636   42.2   0.96 (0.95--0.98)   \<0.0001   0.95 (0.94--0.97)   \<0.0001
                          F Het            1,276         39.0        1,566         37.9      1,661               37.9               1,419   36.8   1,576   33.7   0.98 (0.96--0.99)    0.0051    0.96 (0.94--0.97)   \<0.0001
                          M IDU             460          35.4         343          46.1       280                44.6                234    39.3    243    36.2   1.00 (0.97--1.04)     0.88     0.99 (0.95--1.02)     0.45
                          F IDU             151          31.1         106          40.6       86                 34.9                80     31.3    57     26.3   0.99 (0.92--1.05)     0.65     0.98 (0.92--1.05)     0.53
                          Other             495          44.2         542          47.1       541                40.9                901    36.7   2,257   29.0   0.92 (0.90--0.94)   \<0.0001   0.92 (0.90--0.94)   \<0.0001
  East                     MSM               47          44.7          39          43.6       67                 26.9                58     25.9    36     36.1   0.91 (0.82--1.01)    0.074     0.90 (0.81--1.01)    0.070
                          M Het              29          44.8          36          38.9       46                 32.6                47     36.2    19     31.6   0.92 (0.81--1.05)     0.21     0.93 (0.81--1.06)     0.27
                          F Het              45          31.1          56          21.4       94                 24.5                94     20.2    59     20.3   0.94 (0.85--1.04)     0.26     0.92 (0.82--1.02)     0.13
                          M IDU              48          31.3          75          17.3       47                 17.0                48     33.3    13     38.5   1.07 (0.94--1.27)     0.30     0.97 (0.85--1.12)     0.68
                          F IDU              30          6.7           15          13.3       25                 4.0                 15     20.0    11     27.3   1.27 (0.98--1.63)    0.068     1.24 (0.94--1.64)     0.14
                          Other              15          60.0          6           83.3       21                 28.6                33     42.4    22     54.6   0.94 (0.80--1.11)     0.45     0.94 (0.77--1.15)     0.55

Adjusted additionally for age, region of origin, and delayed entry into care (≥3 mo between HIV diagnosis and first clinic visit). Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm^3^or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis.

F, female; Het, heterosexual; M, male.

There were 8,187 AIDS/deaths (1,852 deaths, 6,283 AIDS, 52 AIDS/death on the same date) during 327,003 person-years of follow-up. The Kaplan-Meier probability of progression to AIDS/death stratified by late presentation and late presentation with advanced disease is shown in [Figures 3A--3D](#pmed-1001510-g003){ref-type="fig"}. Late presenters or late presenters with advanced disease within each region had a steep increase in probability of new AIDS/death within the first 1 or 2 y following presentation, but followed a similar curve as those who did present late after this period, with some differences between regions (*p*\<0.0001, test for interaction).

![(A--D) Progression to new AIDS/death: role of late presentation or late presentation with advanced disease: COHERE 2000--2011.\
(A) Southern Europe. (B) Central Europe. (C) Northern Europe. (D) Eastern Europe. LP, diagnosed with HIV with a CD4 count below 350/mm^3^ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Presentation with advanced disease (AD): diagnosed with HIV with a CD4 count below 200/mm^3^ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis.](pmed.1001510.g003){#pmed-1001510-g003}

This finding is explored in [Table 3](#pmed-1001510-t003){ref-type="table"}. Late presentation was associated with the highest rate of AIDS/death in the first year after HIV diagnosis among persons from Southern Europe (adjusted incidence rate ratio \[aIRR\] 13.02; 95% CI 8.19--20.70) and the lowest rate in Eastern Europe (aIRR 6.64; 95% CI 3.55--12.43). In the second year after diagnosis, late presentation was associated with a higher rate of AIDS/death among persons from Southern, Central, and Northern Europe, but was similar in both late and non-late presenters from Eastern Europe. Late presentation was not associated with an increased rate of AIDS/death after the initial 2 y, within any European region of care. Also shown are the results for late presentation with advanced disease, which showed very similar findings. Late presentation was associated with an increased rate of AIDS/death in those presenting with advanced disease beyond 2 y in Southern Europe (aIRR 1.38; 95% CI 1.01--1.88), and only in the first year after diagnosis for those from Eastern Europe (aIRR 6.98; 95% CI 4.22--11.56). Results were similar when excluding patients with unknown or delayed entry into care ([Table S4](#pmed.1001510.s004){ref-type="supplementary-material"}).

10.1371/journal.pmed.1001510.t003

###### Number and percentage of AIDS/deaths and adjusted incidence rate ratios of AIDS/death after HIV diagnosis in COHERE 2000--2011; late presenters versus non late presenters stratified by European region of care and time since presentation.

![](pmed.1001510.t003){#pmed-1001510-t003-3}

  *European Region of Care*                           *Years since Diagnosis*   *n* (%) AIDS/        Univariate        Multivariate                         
  -------------------------------------------------- ------------------------- --------------- ---------------------- -------------- ---------------------- ----------
  **Late presenters versus non late presenters**                                                                                                            
  South                                                         \<1              376 (95.2)     15.83 (9.97--25.10)      \<0.0001     13.02 (8.19--20.70)    \<0.0001
  Central                                                       \<1             2,228 (93.5)    12.87 (10.94--15.14)     \<0.0001     11.24 (9.54--13.25)    \<0.0001
  North                                                         \<1             1,528 (91.9)    10.70 (8.96--12.75)      \<0.0001      9.30 (7.79--11.11)    \<0.0001
  East                                                          \<1               75 (86.2)      7.55 (4.10--13.88)      \<0.0001      6.64 (3.55--12.43)    \<0.0001
  South                                                        1--2               56 (70.0)      1.93 (1.20--3.11)        0.0070       1.55 (0.94--2.53)      0.081
  Central                                                      1--2              374 (69.5)      2.03 (1.69--2.43)       \<0.0001      1.78 (1.48--2.15)     \<0.0001
  North                                                        1--2              280 (64.7)      1.72 (1.42--2.10)       \<0.0001      1.57 (1.29--1.93)     \<0.0001
  East                                                         1--2               16 (45.7)      1.02 (0.53--1.99)         0.95        0.94 (0.47--1.91)       0.87
  South                                                         \>2              112 (64.4)      1.47 (1.08--2.01)        0.015        1.21 (0.88--1.67)       0.24
  Central                                                       \>2              726 (55.7)      1.04 (0.94--1.16)         0.45        0.95 (0.85--1.06)       0.35
  North                                                         \>2              535 (52.5)      0.96 (0.84--1.08)         0.47        0.88 (0.78--1.00)      0.049
  East                                                          \>2               35 (45.5)      0.90 (0.57--1.41)         0.64        0.80 (0.50--1.29)       0.36
  **Advanced disease versus non-advanced disease**                                                                                                          
  South                                                         \<1              356 (90.1)     17.13 (12.31--23.85)     \<0.0001     14.63 (10.46--20.47)   \<0.0001
  Central                                                       \<1             2,069 (86.8)    14.96 (13.28--16.84)     \<0.0001     13.27 (11.77--14.98)   \<0.0001
  North                                                         \<1             1,437 (86.4)    14.14 (12.29--16.27)     \<0.0001     12.45 (10.80--14.37)   \<0.0001
  East                                                          \<1               64 (73.6)      7.85 (4.88--12.65)      \<0.0001      6.98 (4.22--11.56)    \<0.0001
  South                                                        1--2               48 (60.0)      2.89 (1.85--4.52)       \<0.0001      2.31 (1.46--3.68)      0.0004
  Central                                                      1--2              243 (45.2)      1.88 (1.59--2.23)       \<0.0001      1.62 (1.36--1.93)     \<0.0001
  North                                                        1--2              194 (44.8)      1.80 (1.49--2.17)       \<0.0001      1.61 (1.32--1.96)     \<0.0001
  East                                                         1--2               9 (25.7)       0.99 (0.46--2.11)         0.97        0.87 (0.39--1.94)       0.73
  South                                                         \>2               86 (49.7)      1.72 (1.28--2.32)        0.0004       1.38 (1.01--1.88)      0.041
  Central                                                       \>2              463 (35.5)      1.17 (1.05--1.31)        0.0061       1.06 (0.94--1.19)       0.32
  North                                                         \>2              351 (34.4)      1.02 (0.90--1.17)         0.72        0.94 (0.82--1.07)       0.33
  East                                                          \>2               21 (27.3)      0.86 (0.52--1.41)         0.54        0.75 (0.44--1.29)       0.30

Adjusted additionally for age, region of origin, delayed entry into care (≥3 mo between HIV diagnosis and first clinic visit), and HIV-exposure group. Late presentation: presenting for care with a CD4 count below 350/mm^3^ or presenting with an AIDS defining event regardless of the CD4 count, in the 6 mo following presentation. Advanced disease: presenting for care with a CD4 count below 200/mm^3^or presenting with an AIDS defining event, regardless of CD4 cell count, in the 6 mo following presentation.

Figures are *n* (%) of clinical events (AIDS/deaths) in late presenters or late presenters with advanced disease.

The definition of late presentation or presentation with advanced disease required that a CD4 count was measured within 6 mo of diagnosis. [Table S5](#pmed.1001510.s005){ref-type="supplementary-material"} considers the odds of having missing CD4 count data, which was consistently higher in Eastern Europe compared to Southern Europe in all HIV-exposure groups. The proportion of late presenters and late presenters with advanced disease varied quite widely, especially in Eastern Europe, as shown in sensitivity analyses in [Table 4](#pmed-1001510-t004){ref-type="table"}. Changing the requirement for the CD4 count to be measured within 1 mo or 12 mo of diagnosis did not greatly alter the proportion of late presenters or late presenters with advanced disease, while assuming those without a CD4 count were late presenters increased the proportion of late presenters to 61.9% overall (63,467/102,532) and 73.8% in Eastern Europe (1,781/2,413). Conversely, assuming that those without a CD4 count and without AIDS were not late presenters lowered the proportion of late presenters to 45.1% overall (46,242/102,532) and to 26.0% in Eastern Europe (627/2,413).

10.1371/journal.pmed.1001510.t004

###### Sensitivity analyses showing the proportion of late presenters or late presenters with advanced disease using different inclusion criteria for CD4 count at HIV diagnosis: COHERE 2000--2011.

![](pmed.1001510.t004){#pmed-1001510-t004-4}

  Characteristic             Region    *n* Late Presenters and Presenters with Advanced Disease   CD4 Measured within *x* Months of HIV Diagnosis   First CD4, Irrespective of Date   No CD4 in First 6 mo = LP/AD   No CD4 in First 6 mo Not LP/AD            
  ------------------------- --------- ---------------------------------------------------------- ------------------------------------------------- --------------------------------- ------------------------------ -------------------------------- --------- ---------
  All patients                                                Total *n*                                               67,338                                    84,524                           88,507                          98,743               102,532   102,532
                                                                LP (%)                                                 54.7                                      53.8                             53.5                            52.6                 61.9      45.1
                                                                AD (%)                                                 34.5                                      33.2                             32.7                            31.4                 45.0      28.1
  European region of care     South                           Total *n*                                                5,491                                     7796                            8,122                           8,788                 8,937     8,937
                                                                LP (%)                                                 58.2                                      57.0                             56.8                            56.9                 62.5      50.5
                                                                AD (%)                                                 38.9                                      36.9                             36.4                            36.0                 44.9      32.9
                             Central                          Total *n*                                               28,491                                    39,949                           42,587                          50,096               50,729    50,729
                                                                LP (%)                                                 56.1                                      54.4                             53.9                            52.5                 64.1      43.5
                                                                AD (%)                                                 35.3                                      33.0                             32.2                            30.3                 47.3      26.7
                              North                           Total *n*                                               17,300                                    35,583                           36,330                          37,488               40,453    40,453
                                                                LP (%)                                                 53.0                                      52.7                             52.5                            52.2                 68.4      47.0
                                                                AD (%)                                                 33.0                                      32.8                             32.6                            32.2                 40.9      29.5
                              East                            Total *n*                                                 724                                      1,196                           1,468                           2,371                 2413      2,413
                                                                LP (%)                                                 48.2                                      47.2                             46.1                            45.3                 73.8      26.0
                                                                AD (%)                                                 30.8                                      28.7                             27.3                            23.7                 64.7      16.9

Late presentation: diagnosed with HIV with a CD4 count below 350/mm^3^ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm^3^or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis.

Corresponds to main analyses presented in [Results](#s4){ref-type="sec"}.

AD, advanced disease; LP, late presenter.

Discussion {#s5}
==========

This study included almost 85,000 persons diagnosed with HIV across Europe after 1 January 2000 and found over half were late presenters and one-third presented with advanced disease using the HIV in Europe definition [@pmed.1001510-Antinori1]. The study focused on regional differences within HIV exposure groups, providing important information for health care providers and for future testing initiatives. Overall, late presentation decreased, and especially in MSMs. However, late presentation remains a significant issue across Europe and in all HIV exposure groups. Late presentation increased in male IDUs and female heterosexuals from Southern and IDUs in Eastern Europe. Late presentation was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, although this also varied across Europe. Earlier and more widespread testing, timely referrals after testing positive, as well as improved retention in care strategies are required to further reduce the incidence of late presentation.

The prevalence of late presentation was similar to that reported from other recent European studies [@pmed.1001510-Zoufaly1]--[@pmed.1001510-Vives1], as is the decrease in late presentation [@pmed.1001510-Helleberg1],[@pmed.1001510-Ndiaye1]. Our study is unique in its ability to report continent-wide changes within HIV exposure groups over a significant period of time. The decreases in late presentation are likely associated with changes to provider initiated HIV testing policies and the massive scale-up of antenatal screening for HIV [@pmed.1001510-European2],[@pmed.1001510-World2]. Factors associated with late presentation in this and previous studies included non-MSMs HIV-exposure group [@pmed.1001510-Girardi1],[@pmed.1001510-Sabin1],[@pmed.1001510-Zoufaly1],[@pmed.1001510-Camoni1],[@pmed.1001510-Vives1],[@pmed.1001510-deOlalla1], older age [@pmed.1001510-Girardi1],[@pmed.1001510-Zoufaly1],[@pmed.1001510-Camoni1]--[@pmed.1001510-Ndiaye1],[@pmed.1001510-Castilla1], and non-European origin [@pmed.1001510-Zoufaly1],[@pmed.1001510-Vives1],[@pmed.1001510-Ndiaye1],[@pmed.1001510-deOlalla1],[@pmed.1001510-Couturier1]. Reasons for the increase in late presentation among IDUs in Eastern Europe and heterosexual females and male IDUs from Southern Europe may include suboptimal health care offered to these populations, differences in characteristics that we were unable to adjust for, such as socioeconomic status, the pattern of the underlying epidemic, and appearance of symptoms that may ultimately promote presentation for care [@pmed.1001510-Mathers1],[@pmed.1001510-Dickson1]. Not all persons recommended for testing undergo testing for a variety of reasons, including stigmatisation, discrimination, criminalisation laws, lack of knowledge, or perceived risk [@pmed.1001510-Yazdanpanah1]. Not testing inevitably leads to later presentation and initiation of ART, despite the fact that an alarmingly high proportion of the late presenters have been in contact with the health system in the years preceding HIV diagnosis [@pmed.1001510-Ndiaye1],[@pmed.1001510-Sullivan1].

As reported by others, late presentation or presentation with advanced disease was associated with a significantly increased incidence of AIDS/deaths [@pmed.1001510-Chadborn1],[@pmed.1001510-Samet1]. We found an increased incidence of AIDS/death, particularly in the first year after HIV diagnosis [@pmed.1001510-Lanoy1],[@pmed.1001510-Helleberg1],[@pmed.1001510-Delpierre1]. There was also significant regional variation, with a 13-fold increased rate in persons in care in Southern Europe and a 6-fold increased rate in Eastern Europe. There was a small increased rate of AIDS/death associated with late presentation in the second year after diagnosis, with the exception of Eastern Europe, and no differences after this time. Morbidity and mortality among HIV-positive individuals in Eastern Europe has been reported to be particularly poor in EuroSIDA [@pmed.1001510-Reekie1], the only contributor to COHERE with data from Eastern Europe. Unfortunately, COHERE does not have additional data on factors such as whether individuals are current IDUs, on opiate substitution therapy, or alcohol dependant, all of which may contribute to clinical progression after HIV diagnosis and which likely vary significantly across regions.

Collaborations such as the HIV in Europe initiative have helped raise awareness of HIV testing, and developed an indicator disease testing strategy, whereby all persons presenting for care for a number of indicator diseases are routinely tested for HIV [@pmed.1001510-Sullivan1]. Despite this and other strategies, individuals continue to test late for HIV with consequences in terms of a poor prognosis, an increased risk of onward HIV transmission, increased costs to the health system, and suboptimal benefits of ART [@pmed.1001510-Antinori1],[@pmed.1001510-Girardi2]. Increasing awareness of HIV risk factors, increased opportunities for testing, reducing barriers to testing, and increasing the availability of effective ART will help address ongoing HIV transmission across Europe, and especially in Eastern Europe where the number of newly diagnosed infections continues to be very high [@pmed.1001510-Jolley1].

Persons were required to have a CD4 count measured within 6 mo of presentation to be included in analyses. If those with missing CD4 counts were assumed late presenters, the proportion of late presenters rose to 62% overall and 74% in Eastern Europe, with 45% overall and 65% from Eastern Europe having advanced disease. Accurate information on CD4 count at presentation is essential for monitoring late presentation, a recent report suggested 18 of 28 countries routinely monitored CD4 count at presentation, and only 11 had information on at least 50% of persons testing HIV positive [@pmed.1001510-Likatavicius1]. Missing CD4 counts were consistently more likely in persons from Eastern Europe ([Table S4](#pmed.1001510.s004){ref-type="supplementary-material"}) among all HIV exposure categories. Persons from Eastern Europe were exclusively included from the EuroSIDA cohort (details at [www.cphiv.dk](http://www.cphiv.dk)). Participating sites are typically centres of excellence, likely not representative of all persons in the region [@pmed.1001510-Global1]. Further, inclusion criteria include a pre-booked clinic outpatient appointment, meaning persons have to survive long enough to be recruited to EuroSIDA, which may have excluded a number of late presenters. Persons from Eastern Europe are known to have a poor prognosis [@pmed.1001510-Reekie1], and CD4 count may be more likely to be missing in those who die before a CD4 count is measured [@pmed.1001510-Johnson1]. As a result, we are likely underestimating the proportion of and consequences of late presentation in this region.

Some limitations of the study should be noted. Date of HIV infection was assumed to be the date of first clinic visit or enrolment into the participating cohort. We performed sensitivity analyses excluding patients where HIV-test date was not reported to COHERE with highly consistent results ([Tables S2](#pmed.1001510.s002){ref-type="supplementary-material"} and [S3](#pmed.1001510.s003){ref-type="supplementary-material"}). Late presentation and delayed entry into care can be thought of as two distinct issues with different risk factors, interventions, and outcomes [@pmed.1001510-Girardi1],[@pmed.1001510-Ndiaye1],[@pmed.1001510-Turner1]. Late presentation reflects patients who are unaware of their HIV infection and do not test until their CD4 count has declined, while delayed entry into care reflects persons who are aware of their HIV status but chose not to seek care for their HIV. Less than 10% of our patient population had delayed entry into care, although this information was only available for a minority of patients. We excluded cohorts including only seroconverters from our analyses, because persons in these cohorts are unlikely to be late presenters. However, inclusion of these cohorts did not substantially alter our findings ([Table S2](#pmed.1001510.s002){ref-type="supplementary-material"}). Local regulations meant information on ethnic origin was not available for over 40% of persons, and likely includes a significant number of migrants who are known to present later for testing [@pmed.1001510-Girardi2].

In summary, while late presentation has decreased over time across Europe, it remains a significant issue across the European continent with implications for both individuals and the public health in most European regions. Late presentation was associated with an increased rate of AIDS/death, particularly in the first year after HIV diagnosis. It is important that earlier HIV testing strategies are targeted to all populations at risk both within the health care system and in community based programs, to ensure timely referrals after testing positive, improved retention in care strategies, and optimal clinical management and initiation of ART in those testing HIV positive.
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